CSF2 and rheumatoid arthritis: Regarding the previous studies, the treatment focused on blocking GM-CSF signaling significantly reduced RA, especially in combination with IL-17 blockade, and brought promising results as a potential alternative therapy, particularly for anti-TNF-α-resistant patients [129].